Mendus AB announced that it will present additional data highlighting the use of the company's proprietary DCOne platform for the ex vivo expansion of NK cells March 30, 2023 at the 8th Annual Innate Killer Cell Summit in La Jolla, San Diego, CA. Natural Killer (NK) cells are part of the innate immune system and form a first line of defense against infections and tumor cells. Memory NK cells are associated with improved tumor cell killing and significantly reduced relapse rates in bone marrow-transplanted leukemia patients.

Memory NK cells therefore hold great therapeutic promise in the treatment of hematological cancers and potentially other tumor types. The data presented March 30, 2023 and at SITC 2022 demonstrate that DCOne cells drive strong expansion of memory NK cells, which subsequently can be used in different therapeutic applications. The presence of activating ligands on the cell surface of DCOne-derived mature dendritic cells provide a mechanistic rationale for the observed expansion of memory NK cells with well-characterized molecular signatures.

The Innate Killer Summit is an industry conference focused on improving patient care by advancing the understanding and enhancing of innate immune cell therapies. On March 30, 3.15pm PST (00:15 CET) Mendus' CEO Erik Manting, PhD, will hold a presentation titled “Developing Expansion Protocols to Enrich for Memory Phenotypes to Produce Quality over Quantity in Final NK Cell Therapy Products” as part of the Clinical Scale Manufacturing track. During the conference, Dr Manting also chaired a panel discussion titled “Sharing a Vision of the Future for Commercial Scale Manufacturing of Innate Immune Cells” on March 29.